S-606001 has the potential to become the first oral substrate reduction therapy for Pompe diseaseOSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer ...

There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things. Researchers at the University of Basel have now been able to use artificial ...

Privilege in healthcare is shaped by geography, timing and a patient's ability to navigate an unforgiving system while in ...

For most children with complicated pneumonia, a less aggressive treatment approach is favored for those with small or moderate pleural effusions, according to updated guidance. The Infectious Diseases ...

One morning in May 2019, a cardiac surgeon stepped into the operating room at Boston Children’s Hospital more prepared than ever before to perform a high-risk procedure to rebuild a child’s heart. The ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

Research shows tumor debulking in advanced colorectal cancer does not enhance survival outcomes and may increase adverse effects, questioning its efficacy.

What has long been interpreted as permanent and irreversible vascular damage may not be exclusively so. In people with Down syndrome—one of the most robust populations for studying Alzheimer's disease ...

The study analyzed the evolution of white matter hyperintensities (WMH), lesions typically associated with cerebral vascular ...

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.